NAD+: Redox Cofactor, Enzyme Substrate, and the Precursor Problem

NAD+ is a dinucleotide: two nucleotides joined tail to tail through a pyrophosphate bridge. One half carries adenine, the other carries nicotinamide, and the formula for the oxidised form is C21H27N7O14P2 at 663.4 g/mol. The '+' notation refers to the positive charge on the nicotinamide ring nitrogen in the oxidised state, not to the net charge of the molecule, which is anionic at physiological pH because of the phosphates.

All of the redox chemistry happens at one position. Carbon 4 of the nicotinamide ring accepts a hydride ion, converting the aromatic pyridinium ring to a non-aromatic dihydropyridine and producing NADH. Because the reaction is a two-electron hydride transfer at a single site, it is clean, reversible and fast, which is exactly what a cofactor shuttling reducing equivalents through hundreds of dehydrogenase reactions needs to be.

NAD+ should be distinguished from its phosphorylated relative NADP+, which carries an additional phosphate on the adenosine ribose. The two are chemically similar and biologically separate: cells maintain the NAD+/NADH pool largely oxidised to drive catabolism, and the NADP+/NADPH pool largely reduced to drive biosynthesis and antioxidant regeneration. Enzymes discriminate between them, and the pools are not interchangeable.

The most useful thing to understand about NAD+ is that it does two different kinds of work, and only one of them uses it up.

In its redox role, NAD+ is catalytic. Glycolysis, the tricarboxylic acid cycle and fatty acid oxidation reduce it to NADH; the electron transport chain and cytosolic dehydrogenases oxidise it back. Molecules cycle through this many times, and the pool size stays roughly constant. Flux through this system is enormous relative to the pool, which is why the NAD+/NADH ratio is informative about metabolic state while the absolute amount changes slowly.

In its signalling role, NAD+ is a consumable. Sirtuins, a family of NAD+-dependent deacylases, cleave the nicotinamide-ribose bond during catalysis, releasing nicotinamide and 2'-O-acetyl-ADP-ribose. PARP enzymes, activated by DNA strand breaks, consume NAD+ in bulk to build poly(ADP-ribose) chains. CD38, a cell-surface glycohydrolase, degrades NAD+ to ADP-ribose and cyclic ADP-ribose. Every one of these reactions destroys the cofactor.

This is the mechanistic reason NAD+ availability became a research question at all. Imai and Guarente set out the argument in 2014: if sirtuin activity depends on NAD+ concentration, and if consuming enzymes compete for the same pool, then NAD+ levels are not an inert housekeeping detail but a node where metabolic state feeds into gene regulation and DNA repair.

Because consuming enzymes destroy NAD+ continuously, cells must resynthesise it continuously. Three routes exist. The de novo pathway builds NAD+ from tryptophan through the kynurenine pathway; it is real but comparatively low-flux in most tissues. The Preiss-Handler pathway starts from nicotinic acid. The salvage pathway starts from nicotinamide, which is precisely what the consuming enzymes release.

The salvage pathway dominates in mammals, and its logic is tidy: nicotinamide phosphoribosyltransferase (NAMPT) attaches a phosphoribosyl group to nicotinamide to make nicotinamide mononucleotide (NMN), and nicotinamide mononucleotide adenylyltransferases (NMNAT1, NMNAT2, NMNAT3) attach an AMP moiety to make NAD+. The three NMNAT isoforms sit in different compartments - nucleus, cytosol and mitochondria respectively - which is part of why NAD+ pools are compartmentalised rather than uniform.

NAMPT is the rate-limiting enzyme, which makes it the principal control point. It is also the reason nicotinamide riboside is pharmacologically interesting: NR enters the pathway downstream of NAMPT via nicotinamide riboside kinases, bypassing the bottleneck. These are the mechanistic facts on which precursor strategies rest, and they are well established in cell and animal systems.

This is the interpretive crux of the NAD+ literature, and skipping it makes most of the field unreadable. NAD+ is a large, doubly negatively charged dinucleotide. Molecules with those properties do not diffuse across lipid bilayers, and no dedicated plasma-membrane transporter for intact NAD+ has been established in mammalian cells.

What happens to extracellular NAD+ instead is enzymatic dismantling. Cell-surface enzymes - CD38, CD73, and ENPP family members - hydrolyse nucleotides stepwise, so extracellular NAD+ tends to be converted toward NMN, then toward nicotinamide riboside and nicotinamide, which are smaller and for which transport routes do exist. The review by Chini and colleagues examines this extracellular metabolism in detail and is the source to read on it.

The consequence for reading the literature is direct. When an experiment adds NAD+ to cells or an organism and observes a change in the intracellular NAD+ pool, the parsimonious interpretation is not that NAD+ crossed the membrane; it is that surface enzymes degraded it and the fragments were salvaged. Distinguishing 'NAD+ got in' from 'precursors got in' requires isotope tracing, not concentration measurement.

This is also why the compound and its precursors should not be discussed interchangeably. A finding about nicotinamide riboside is a finding about nicotinamide riboside.

Human interventional work on NAD+ biology is almost entirely precursor work. The 2017 open-label study by Airhart and colleagues is a representative early example: it characterised the pharmacokinetics of nicotinamide riboside in healthy volunteers and measured blood NAD+ levels. Later randomised trials, including work on nicotinamide mononucleotide formulations, have extended this. The consistent result across these studies is that circulating NAD+ and related metabolites can be raised by oral precursors.

Raising a biomarker is a genuine finding and a limited one. It establishes that the salvage machinery responds to substrate supply in humans. It does not establish that any clinical outcome follows, and the trials that would answer that question - adequately powered, randomised, with hard endpoints and long follow-up - are largely still absent. Reviews of the translational literature have made this point repeatedly.

The frequently repeated claim that tissue NAD+ declines with age deserves the same care. That decline is supported by tissue measurement studies and by a substantial preclinical literature in which restoring NAD+ in aged rodents improves measured parameters. Those are animal results. The inference from 'NAD+ declines with age in humans' through 'restoring it in mice helps' to 'restoring it in humans helps' spans a gap that human interventional data have not yet closed.

What is not in dispute is the biochemistry. NAD+ as a redox carrier and as a substrate for sirtuins, PARPs and CD38 is textbook enzymology, characterised in detail, and it is the reason lyophilised NAD+ is a routine reagent in enzymology and redox-cycling assays. The uncertainty is not about what NAD+ does inside a cell; it is about what supplying it from outside accomplishes.